Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Kevin Gray and Rachel Tomko.
Connection Strength

10.169
  1. Sex Differences in Subjective and Behavioral Responses to Stressful and Smoking Cues Presented in the Natural Environment of Smokers. Nicotine Tob Res. 2020 01 27; 22(1):81-88.
    View in: PubMed
    Score: 0.721
  2. Depressive symptoms and cannabis use in a placebo-controlled trial of N-Acetylcysteine for adult cannabis use disorder. Psychopharmacology (Berl). 2020 Feb; 237(2):479-490.
    View in: PubMed
    Score: 0.711
  3. An electronic, smart lighter to measure cigarette smoking: A pilot study to assess feasibility and initial validity. Addict Behav. 2019 11; 98:106052.
    View in: PubMed
    Score: 0.695
  4. Methods to reduce the incidence of false negative trial results in substance use treatment research. Curr Opin Psychol. 2019 12; 30:35-41.
    View in: PubMed
    Score: 0.673
  5. Corrigendum to The role of depressive symptoms in treatment of adolescent cannabis use disorder with N-Acetylcysteine Addictive Behaviors 85 (2018) 26-30. Addict Behav. 2019 Feb; 89:263.
    View in: PubMed
    Score: 0.658
  6. N-acetylcysteine: A potential treatment for substance use disorders. Curr Psychiatr. 2018 06; 17(6):30-36, 41-42, 55.
    View in: PubMed
    Score: 0.643
  7. The role of depressive symptoms in treatment of adolescent cannabis use disorder with N-Acetylcysteine. Addict Behav. 2018 10; 85:26-30.
    View in: PubMed
    Score: 0.642
  8. Incremental validity of estimated cannabis grams as a predictor of problems and cannabinoid biomarkers: Evidence from a clinical trial. Drug Alcohol Depend. 2018 01 01; 182:1-7.
    View in: PubMed
    Score: 0.618
  9. Alcohol consumption as a predictor of reactivity to smoking and stress cues presented in the natural environment of smokers. Psychopharmacology (Berl). 2017 Feb; 234(3):427-435.
    View in: PubMed
    Score: 0.578
  10. Personalizing substance use treatment based on pre-treatment impulsivity and sensation seeking: A review. Drug Alcohol Depend. 2016 Oct 01; 167:1-7.
    View in: PubMed
    Score: 0.566
  11. Distress tolerance and reactivity to negative affective cues in naturalistic environments of cannabis-using emerging adults. Drug Alcohol Depend. 2022 09 01; 238:109588.
    View in: PubMed
    Score: 0.214
  12. Varenicline as a treatment for cannabis use disorder: A placebo-controlled pilot trial. Drug Alcohol Depend. 2021 12 01; 229(Pt B):109111.
    View in: PubMed
    Score: 0.202
  13. Evaluating N-acetylcysteine for early and end-of-treatment abstinence in adult cigarette smokers. Drug Alcohol Depend. 2021 08 01; 225:108815.
    View in: PubMed
    Score: 0.199
  14. Cannabis and Alcohol Co-Use in a Smoking Cessation Pharmacotherapy Trial for Adolescents and Emerging Adults. Nicotine Tob Res. 2020 07 16; 22(8):1374-1382.
    View in: PubMed
    Score: 0.186
  15. Making pharmacotherapy trials for substance use disorder more efficient: Leveraging real-world data capture to maximize power and expedite the medication development pipeline. Drug Alcohol Depend. 2020 04 01; 209:107897.
    View in: PubMed
    Score: 0.181
  16. Efficacy and Safety of Varenicline for Adolescent Smoking Cessation: A Randomized Clinical Trial. JAMA Pediatr. 2019 12 01; 173(12):1146-1153.
    View in: PubMed
    Score: 0.178
  17. Measuring Within-Individual Cannabis Reduction in Clinical Trials: A Review of the Methodological Challenges. Curr Addict Rep. 2019 Dec; 6(4):429-436.
    View in: PubMed
    Score: 0.178
  18. Adolescent Substance Use Disorder Treatment: an Update on Evidence-Based Strategies. Curr Psychiatry Rep. 2019 09 14; 21(10):96.
    View in: PubMed
    Score: 0.176
  19. Pharmacological Treatment of Youth Substance Use Disorders. J Child Adolesc Psychopharmacol. 2019 08; 29(7):559-572.
    View in: PubMed
    Score: 0.171
  20. Blunts versus joints: Cannabis use characteristics and consequences among treatment-seeking adults. Drug Alcohol Depend. 2019 05 01; 198:105-111.
    View in: PubMed
    Score: 0.170
  21. Tobacco use during cannabis cessation: Use patterns and impact on abstinence in a National Drug Abuse Treatment Clinical Trials Network study. Drug Alcohol Depend. 2018 11 01; 192:59-66.
    View in: PubMed
    Score: 0.163
  22. Acceptability and compliance with a remote monitoring system to track smoking and abstinence among young smokers. Am J Drug Alcohol Abuse. 2018; 44(5):561-570.
    View in: PubMed
    Score: 0.160
  23. Using REDCap for ambulatory assessment: Implementation in a clinical trial for smoking cessation to augment in-person data collection. Am J Drug Alcohol Abuse. 2019; 45(1):26-41.
    View in: PubMed
    Score: 0.158
  24. The effect of N-acetylcysteine on alcohol use during a cannabis cessation trial. Drug Alcohol Depend. 2018 04 01; 185:17-22.
    View in: PubMed
    Score: 0.157
  25. Reductions in cannabis use are associated with improvements in anxiety, depression, and sleep quality, but not quality of life. J Subst Abuse Treat. 2017 10; 81:53-58.
    View in: PubMed
    Score: 0.152
  26. A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults. Drug Alcohol Depend. 2017 08 01; 177:249-257.
    View in: PubMed
    Score: 0.150
  27. Alcohol use during a trial of N-acetylcysteine for adolescent marijuana cessation. Addict Behav. 2016 12; 63:172-7.
    View in: PubMed
    Score: 0.142
  28. Low Pretreatment Impulsivity and High Medication Adherence Increase the Odds of Abstinence in a Trial of N-Acetylcysteine in Adolescents with Cannabis Use Disorder. J Subst Abuse Treat. 2016 Apr; 63:72-7.
    View in: PubMed
    Score: 0.136
  29. N-acetylcysteine does not alter neurometabolite levels in non-treatment seeking adolescents who use alcohol heavily: A?preliminary randomized clinical trial. Neuropsychopharmacology. 2023 Mar 06.
    View in: PubMed
    Score: 0.056
  30. Determining the impact of cannabis use and severity on tobacco cessation outcomes: study protocol for a prospective tobacco treatment trial. BMC Psychol. 2023 Jan 25; 11(1):25.
    View in: PubMed
    Score: 0.055
  31. Characterization of Salivary Progesterone in Female Smokers. Nicotine Tob Res. 2022 10 26; 24(11):1829-1833.
    View in: PubMed
    Score: 0.055
  32. Assessment of patient perception of treatment assignment and patient-reported outcomes in a cannabis use disorder trial. Am J Drug Alcohol Abuse. 2022 Nov 02; 48(6):651-661.
    View in: PubMed
    Score: 0.054
  33. A pilot feasibility study of a behavioral intervention for nicotine vaping cessation among young adults delivered via telehealth. Drug Alcohol Depend. 2022 03 01; 232:109311.
    View in: PubMed
    Score: 0.052
  34. The estimand framework and its application in substance use disorder clinical trials: a case study. Am J Drug Alcohol Abuse. 2021 11 02; 47(6):658-663.
    View in: PubMed
    Score: 0.051
  35. Correspondence Between Perceived Pubertal Development and Hormone Levels in 9-10 Year-Olds From the Adolescent Brain Cognitive Development Study. Front Endocrinol (Lausanne). 2020; 11:549928.
    View in: PubMed
    Score: 0.049
  36. Examining sex, adverse childhood experiences, and oxytocin on neuroendocrine reactivity in smokers. Psychoneuroendocrinology. 2020 10; 120:104752.
    View in: PubMed
    Score: 0.046
  37. Increases in endogenous progesterone attenuate smoking in a cohort of nontreatment seeking women: An exploratory prospective study. Addict Biol. 2021 03; 26(2):e12918.
    View in: PubMed
    Score: 0.046
  38. The influence of gender and oxytocin on stress reactivity, cigarette craving, and smoking in a randomized, placebo-controlled laboratory relapse paradigm. Psychopharmacology (Berl). 2020 Feb; 237(2):543-555.
    View in: PubMed
    Score: 0.045
  39. Behavioral Treatments for Adolescent Cannabis Use Disorder: a Rationale for Cognitive Retraining. Curr Addict Rep. 2019 Dec; 6(4):437-442.
    View in: PubMed
    Score: 0.044
  40. Impact of cannabis legalization on treatment and research priorities for cannabis use disorder. Int Rev Psychiatry. 2018 06; 30(3):216-225.
    View in: PubMed
    Score: 0.040
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.